For a patient already taking gliclazide 120 mg and basal insulin with eGFR ≥45 mL/min/1.73 m², is empagliflozin (Jardiance) 25 mg the standard maintenance dose, or can the patient remain on 10 mg long‑term?

Empagliflozin Dosing: 10 mg vs 25 mg for Long-Term Maintenance

For a patient with eGFR ≥45 mL/min/1.73 m² already on gliclazide and basal insulin, empagliflozin 10 mg is the appropriate long-term maintenance dose, and there is no need to escalate to 25 mg. The higher dose does not provide additional cardiovascular or renal benefits in this eGFR range and offers only marginal additional glucose-lowering effect.

Evidence-Based Rationale

FDA-Approved Dosing and Renal Function

The FDA label for empagliflozin (Jardiance) clearly states that both 10 mg and 25 mg are approved maintenance doses 1. The key distinction is based on renal function:

• eGFR ≥45 mL/min/1.73 m²: No dose adjustment required; both 10 mg and 25 mg can be used 1
• eGFR <45 mL/min/1.73 m²: Do not initiate; discontinue if eGFR persistently falls below 45 1

Guideline Recommendations Support 10 mg as Sufficient

The 2022 ADA/KDIGO consensus explicitly states: "Empagliflozin 10 mg daily" for patients with eGFR ≥45 mL/min/1.73 m² 2. The guideline includes a critical footnote: "Higher dose can be used but is not effective for glucose lowering and does not offer further clinical benefit in this range of eGFR" 2.

This is reinforced by the 2020 KDIGO guideline 3 and the 2025 ADA Standards of Care 4, which emphasize that SGLT2 inhibitors should be selected based on documented kidney or cardiovascular benefits, not dose escalation.

Clinical Trial Evidence: No Superiority of 25 mg

The EMPA-REG OUTCOME trial—the landmark cardiovascular outcomes study—used both 10 mg and 25 mg doses and found equivalent cardiovascular and renal benefits 5. The trial demonstrated:

• 38% reduction in cardiovascular death (pooled doses)
• 39% reduction in incident or worsening nephropathy
• No dose-dependent difference in these outcomes

A 2022 network meta-analysis 6 found that while 25 mg showed slightly better HbA1c reduction than 10 mg, the difference was clinically marginal (SUCRA ranking: 25 mg > 10 mg for HbA1c, but 10 mg had better safety profile). When considering efficacy, safety, and adverse events together, 25 mg performed best only when glucose control was the primary concern—but for patients already on insulin and sulfonylurea, this is not the priority.

Pharmacokinetic and Pharmacodynamic Considerations

Research demonstrates that empagliflozin exhibits dose-proportional pharmacokinetics 1, 7:

• 10 mg: Mean urinary glucose excretion ~64 g/day 1, 7
• 25 mg: Mean urinary glucose excretion ~78 g/day 1, 7

This represents only a 22% increase in glucose excretion with dose doubling, while systemic exposure increases proportionally (AUC: 1,870 vs 4,740 nmol·h/L) 1. The incremental glucose-lowering benefit diminishes as eGFR declines 8, making higher doses even less justified in patients with any degree of renal impairment.

Clinical Decision Algorithm

For your patient (eGFR ≥45, on gliclazide + insulin):

1. Current dose 10 mg? → Continue 10 mg indefinitely

   • Provides full cardiovascular and renal protection 2, 9
   • Lower risk of volume depletion and genital infections 2, 4
   • Adequate glucose-lowering when combined with existing regimen

2. Considering dose escalation? → Assess the indication:

   • If for glucose control: Consider reducing gliclazide or insulin instead of increasing empagliflozin (reduces hypoglycemia risk) 3, 4
   • If for CV/renal protection: 10 mg already provides maximal benefit 2, 5
   • If eGFR 30-44: Maintain 10 mg; do NOT increase to 25 mg 2

3. Monitor for:

   • eGFR decline: Expect initial 2-5 mL/min dip (transient, not harmful) 3, 10
   • Volume status: Especially if age ≥75 or on loop diuretics 2, 4
   • Genital infections: More common with higher doses 2

Common Pitfalls to Avoid

Pitfall #1: Assuming 25 mg is "standard" because it's the higher dose

• Reality: Both doses are FDA-approved maintenance doses; 10 mg is sufficient for cardiorenal protection 2, 1

Pitfall #2: Escalating to 25 mg for better glucose control in patients on insulin/sulfonylurea

• Reality: This increases hypoglycemia risk without meaningful HbA1c benefit 3, 4. Instead, reduce insulin or gliclazide dose 3

Pitfall #3: Discontinuing empagliflozin when eGFR drops below 45

• Reality: Continue for cardiovascular/renal benefit until dialysis 2, 3, 9. The 2022 ADA/KDIGO guideline explicitly states: "Once initiated, the SGLT2i can be continued at lower levels of eGFR" 2

Pitfall #4: Using 25 mg in patients with eGFR 30-44

• Reality: Guidelines recommend 10 mg only in this range 2. Higher doses offer no additional benefit and may increase adverse events

Practical Considerations

For patients already stable on 10 mg:

• No need to escalate unless HbA1c remains >1% above target despite optimization of other agents
• Even then, adding a GLP-1 RA is preferred over increasing empagliflozin 2, 4

For new initiations:

• Start with 10 mg in all patients with eGFR ≥45 2, 1
• Reserve 25 mg only for younger patients (age <65) with eGFR >60 who need aggressive glucose lowering and are not on insulin/sulfonylurea 4, 6

Cost and adherence:

• Both doses typically cost the same; no financial advantage to 25 mg
• Lower dose may improve tolerability and reduce discontinuation 6, 7

2, 5, 3, 4, 9, 1, 6